Not Signed In - Data From Phase III Comparative Study Show Campath(R) Superior To Chlorambucil As A First-line Therapy In B-CLL
Tue, 12 Dec 2006 08:00 AM EST
... Genzyme Corporation (Nasdaq: GENZ) and Berlex Inc., a U.S. affiliate of Schering AG, Germany (FSE: SCH), majority-owned by the Bayer Group, today announced results from CAM307, an international Phase III clinical trial comparing Campath(R) (alemtuzumab) with chlorambucil in previously untreated patients with B-cell chronic lymphocytic leukemia (B-CLL). [click link for full article] ...
Related Topics
- Data & Statistics
- Data Analysis
- Alemtuzumab
- National Data
- Antithrombin III
- Chlorambucil
- Color Therapy
- Music therapy
- Massage therapy
- Pet Therapy
- Physical Therapy
- Chelation therapy
- Natural therapy
- Natural therapies
- Familial Dysautonomia
- Magnet therapy
- Mining
- Superior Vena Cava Syndrome
- Herbal therapy
- Urine therapy
email this page
print this page
bookmark this page
feedback on this page
